Next Article in Journal
Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort
Previous Article in Journal
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer
Open AccessArticle

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer

1
Policy Analysis Inc., Chestnut Hill, MA 02467, USA
2
Novartis Pharmaceuticals Canada Inc., Dorval, QC H9S 1A9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(1), 491-508; https://doi.org/10.3390/curroncol28010051
Received: 25 November 2020 / Revised: 11 December 2020 / Accepted: 8 January 2021 / Published: 14 January 2021
(1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced breast cancer is limited. (2) Methods: Patients’ and physicians’ preferences for treatments for HR+/HER2−, pre-/peri-menopausal advanced breast cancer were assessed by an online discrete choice experiment (DCE). Treatment alternatives were characterized by seven attributes regarding dosing, efficacy, and toxicities, with levels corresponding to those for ribociclib plus a non-steroidal aromatase inhibitor (NSAI), NSAI, and tamoxifen. For patients, impacts of advanced breast cancer on quality of life (QOL) and ability to work/perform activities of daily living also were assessed. Patients were recruited by a Canadian breast cancer patient advocacy group through email and social media. Physicians were recruited by email. (3) Results: Among 118 patients starting the survey, 23 completed ≥ 1 DCE question (19%). Among 271 physicians who were sent the e-mail invitation, 21 completed ≥ 1 DCE question (8%). For both patients and physicians, the increased probability of remaining alive and without cancer progression over 2 years was the most important attribute. A treatment with attributes consistent with ribociclib plus NSAI was chosen by patients and physicians in 70% and 88% of the time, respectively. A substantial proportion of patients reported worrying about future diagnostic tests and their cancer getting worse; (4) Conclusions: Canadian patients and physicians are generally concordant in preference for advanced breast cancer treatments, preferring ribociclib plus NSAI to other options. View Full-Text
Keywords: advanced breast cancer; preferences advanced breast cancer; preferences
Show Figures

Figure 1

MDPI and ACS Style

Stellato, D.; Thabane, M.; Eichten, C.; Delea, T.E. Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer. Curr. Oncol. 2021, 28, 491-508. https://doi.org/10.3390/curroncol28010051

AMA Style

Stellato D, Thabane M, Eichten C, Delea TE. Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer. Current Oncology. 2021; 28(1):491-508. https://doi.org/10.3390/curroncol28010051

Chicago/Turabian Style

Stellato, Daniel; Thabane, Marroon; Eichten, Caitlin; Delea, Thomas E. 2021. "Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer" Curr. Oncol. 28, no. 1: 491-508. https://doi.org/10.3390/curroncol28010051

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop